Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
oh yeah baby !!
Thanks weedy!
Happy Thanksgiving to you, your family, and everybody here.
I am getting ready for the holidays with my family and my work at Nordstrom.
It's all great news any way!
How are you Weedie?
OUPSSS !!! I am 1 week late on that one!!!
PRESS RELEASE
Nov. 13, 2012, 7:00 a.m. EST
NanoViricides Signs Agreement with BASi for Toxicology and Safety Studies
WEST HAVEN, Conn., Nov 13, 2012 (BUSINESS WIRE) -- NanoViricides, Inc. NNVC +10.42% (the "Company") announced today that it has entered into an agreement with Bioanalytical Systems, Inc. BASI 0.00% to conduct drug development studies required for submission of Investigational New Drug (IND) applications to the FDA for its nanoviricides(R) drug candidates against various viral diseases.
The Company has designed the toxicology and safety pharmacology studies that will enable the IND submission and the first-in-human clinical trials of its FluCide(R) investigational anti-influenza product. BASi will conduct the cGLP and non-GLP studies as required (cGLP = current Good Laboratory Practices). These studies are designed to assess overall safety in animals receiving multiple doses of FluCide. Specific safety pharmacology studies will also be conducted to assess the effects of FluCide(R) on the cardiovascular, respiratory and central nervous systems. These studies are required for US FDA IND submission, as well as for applications to conduct human clinical trials in other countries such as Australia.
The design of the studies was reviewed by the FDA in a pre-IND meeting, as previously announced by the Company.
The Company has previously reported successful results of the Company's FluCide(TM) drug candidates in pre-clinical animal studies using two different phylogenetically distinct types of Influenza A, viz. H1N1 and H3N2. The Company has also reported that the drug candidates have been found to be extremely safe in these animal studies. The Company intends to conduct additional efficacy studies as required for the IND application in parallel with the safety/toxicology studies.
The Company anticipates that it will need very large quantities of the drug candidate for these "tox package" studies. The Company has found FluCide to be safe in animals at large dosages, and will need to determine certain safety and toxicology limit parameters. The Company is currently performing scale-up studies in order to produce the necessary quantities of the drug candidate.
About BASi:
BASi, established in 1974 with headquarters in West Lafayette, Indiana, is a pharmaceutical development company providing contract research services and monitoring instruments to the world's leading drug development companies and medical research organizations. With over 30 years of experience, BASi conducts IND-enabling drug safety and toxicology studies at its AAALAC-accredited laboratory located on a 52-acre campus near Evansville, Indiana. BASi has an excellent record of regulatory compliance. All facilities have been inspected by the US FDA with no significant adverse findings. Visit www.BASinc.com for more about BASi.
About NanoViricides:
NanoViricides, Inc. ( www.nanoviricides.com ) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
SOURCE: NanoViricides, Inc.
My wife Norris told me the same thing !!
Well weedie, so far we have wild4nano as our conductor!
Proseco, champagne and martini!
Did I miss something??
FN
I think a lot of us are patient.
And it could be 2 to 3 years or 4 to 7 months.
Wild4Nano,
Wow! What a difference!
I love reading your posts!
FN
Why would you own that stock if you are so negative about it?
That's right! Women, gays and left handed men can cook, control their children, and watch television.
Right-handed men can only do one thing at the time.
If we watch at a football macth there is nothing else that we can do.
This is my wife teaching!
FN
Great!
Let's load the bus!
FN
Well come back Kelt!
Gary,
I am with you!
FN
You should inform yourself !!!!!
You have no idea about what you say.
I am thank you.
Because I know that more news are coming !!!
Wait and see!!!
FN
I love your posts Weedie
You bring a lot to the board!
Thank you!
Les jeux sont faits.
You say 0.50! I say $2.00.
Great news are coming. We are going to have a very interesting Winter.
FN
I hear you but we have more great news coming up !
So there is a high probability that we still have significant increases.
FN
We need to write her an email.
GREAT !!!!!!
And that is very soon!!
We should start organizing!
Are you the chauffeur?
Tomorrow ??
It's happening!
FN
Weedie
WOW!!!! 0.79 !!!!
That feel so good!!!
I love Corsica to!
What about Richard Bronson island?
A dream!!!
Weedie
There will be a lot of people !!!
And the Forze is with you!
No we stay!
And Aznavour the dancing!!
Of course you can !
$20 is the agreement !
No problems with my wife Cherry!
I cannot wait to see that!!!
Yes, we will have more results and other great news.
I expect a very important increase of the stock.
Email Dr Seymour.